European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. (Q52845873)

From Wikidata

Jump to navigation Jump to search

scientific article published on 27 October 2016

Language	Label	Description	Also known as
English	European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk.	scientific article published on 27 October 2016

Statements

scholarly article

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27789571

European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. (English)

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27789571

atherosclerosis

1 reference

based on heuristic

inferred from title

circulatory system

1 reference

based on heuristic

inferred from title

12

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27789571

Alberico L. Catapano

13

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27789571

6

object named as

G Kees Hovingh

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27789571

1

object named as

Ulf Landmesser

1 reference

Europe PubMed Central

8 May 2018

Thomas Lüscher

7

object named as

Thomas F Lüscher

1 reference

Europe PubMed Central

8 May 2018

10

object named as

Olov Wiklund

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27789571

author name string

M. John Chapman

2

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27789571

Michel Farnier

3

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27789571

Baris Gencer

4

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27789571

Stephan Gielen

5

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27789571

David Sinning

8

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27789571

Lale Tokgözoglu

9

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27789571

Jose Luis Zamorano

11

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27789571

European Society of Cardiology (ESC)

14

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27789571

European Atherosclerosis Society (EAS)

15

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27789571

publication date

27 October 2016

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27789571

European Heart Journal

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27789571

38

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27789571

2245-2255

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27789571

29

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27789571

Economic burden of cardiovascular diseases in the enlarged European Union

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

Acute and chronic impact of cardiovascular events on health state utilities

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

A century of cholesterol and coronaries: from plaques to genes to statins

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by repres

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

PCSK9: a key modulator of cardiovascular health

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

Expected impact of applying new 2013 AHA/ACC cholesterol guidelines criteria on the recommended lipid target achievement after acute coronary syndromes.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries--Findings from the EUROASPIRE IV survey

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevati

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

Diagnosis and treatment of familial hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

Efficacy of statins in familial hypercholesterolaemia: a long term cohort study

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

Mortality among patients with familial hypercholesterolemia: a registry-based study in Norway, 1992-2010.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

Impact of postdischarge statin withdrawal on long-term outcomes in patients with acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

An assessment by the Statin Intolerance Panel: 2014 update

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

An assessment by the Statin Muscle Safety Task Force: 2014 update.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

Improvement in LDL-cholesterol levels of patients with familial hypercholesterolemia: Can we do better? Analysis of results obtained during the past two decades in 1669 French subjects

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHW480

21 January 2018

Identifiers

10.1093/EURHEARTJ/EHW480

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27789571

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27789571

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52845873&oldid=2113549272"